permission

Europe is changing its assessment and giving limited approval to lecanemab, a controversial Alzheimer’s disease drug.

The European Medicines Agency (EMA) has re-evaluated the Alzheimer's drug lecanemab and decided to authorize the product. The decision comes…

2 weeks ago

BBVA seeks permission to launch takeover bid for Sabadell

BBVA seeks permission to launch takeover bid for SabadellHumberto Bilbao BBVA has already sent a request for permission of the…

6 months ago